Fig. 2

S100A8/A9 blockade ameliorates septic cardiomyopathy. Endotoxemia was induced in C57Bl/6NrJ mice by intraperitoneal injection of 5 mg/kg LPS. The mice were treated with 30 mg/kg ABR-238901 (ABR) or PBS intraperitoneally at 0 h and 6 h post-LPS. A Experimental timeline for B–C. Blood sampling was performed at 0, 6, 12, 24, 48, 72 and 96 h post-LPS. B Kinetics of S100A8/A9 release. C Bodyweight change, expressed as serial measurements and area under the curve (AUC). D Experimental timeline for E–I. Echocardiography was performed at baseline, 6 h, 12 h and 24 h. E–G Left ventricular ejection fraction (LVEF), stroke volume (LVSV) and cardiac output (LVCO), presented as serial measurements and area under the curve over time. Statistical testing was performed by repeated-measures two-way ANOVA with Fisher’s LSD Test. The p-values on the time-course graphs reflect differences between the treatment groups at the respective time point. Differences in AUC between the groups were assessed using Student’s t-test, following normality assessment with Shapiro–Wilk test. PBS, Phosphate Buffered Saline; ABR, ABR-238901; BW, bodyweight; AUC, area under curve; LVEF, Left ventricular ejection fraction; LVSV, Left ventricular stroke volume; LVCO, Left ventricular cardiac output. Data is represented as mean ± SD. B and C N = 7–15 per group, E–G N = 5 per group